Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction
- 1 June 2015
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 240 (2) , 477-481
Abstract
No abstract availableKeywords
Funding Information
- Junior Faculty grant, IMM
- Stockholm county (ALF 20130053)
- Swedish Heart-Lung Foundation (20130220)
This publication has 38 references indexed in Scilit:
- Inflammation and AtherosclerosisCardiology in Review, 2014
- IL-6 and its receptors in coronary artery disease and acute myocardial infarctionCytokine, 2013
- Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart FailureCirculation: Heart Failure, 2013
- The interleukin-6 pathway and atherosclerosisThe Lancet, 2012
- Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levelsThrombosis and Haemostasis, 2009
- The soluble interleukin 6 receptor: mechanisms of production and implications in diseaseThe FASEB Journal, 2001
- Circulating Interleukin-6 and Interleukin-6 Receptors in Patients with Acute and Recent Myocardial InfarctionCardiology, 2000
- Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy MenCirculation, 2000